Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VTP-850 immunotherapy in biochemically recurrent prostate cancer
NCT05617040Phase 2Terminated
- Sponsor
- Barinthus Biotherapeutics
- Start
- Jan 2023
- Primary completion
- Feb 2025
- Modality
- Viral Vector Vaccines, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of VTP-850 in prostate cancer (PCa), sponsored by Barinthus Biotherapeutics. Started Jan 2023; status: terminated.
02
Drugs
VTP-850
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05617040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05617040.